Guided Therapeutics(GTHP)
$0.11+0.01 (+7.84%)
GTHP
Guided Therapeutics financials statements
$0.11
At close:+0.01 (+7.84%)
Guided Therapeutics (GTHP) Ratios
29 Followers
Guided Therapeutics Ratios
GTHP's free cash flow for Q2 2026 was $-319.00K. For the 2026 fiscal year, GTHP's free cash flow was increased by $0.00 and operating cash flow was $-319.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.09 | 0.19 | 0.29 | 0.62 | 0.29 |
| Quick Ratio | 0.02 | 0.09 | 0.16 | 0.50 | 0.19 |
| Cash Ratio | 0.01 | 0.06 | 0.12 | 0.48 | 0.11 |
| Solvency Ratio | -0.42 | -0.37 | -0.62 | -0.68 | -0.28 |
| Operating Cash Flow Ratio | -0.16 | -0.18 | -0.36 | -0.30 | -0.28 |
| Short-Term Operating Cash Flow Coverage | -0.49 | -0.58 | -1.34 | -1.83 | -1.40 |
| Net Current Asset Value | $ -6.72M | $ -5.07M | $ -4.08M | $ -3.25M | $ -5.85M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 2.22 | 1.57 | 1.23 | 0.67 | 1.42 |
| Debt-to-Equity Ratio | -0.49 | -0.44 | -0.54 | -0.78 | -0.53 |
| Debt-to-Capital Ratio | -0.96 | -0.79 | -1.18 | -3.65 | -1.14 |
| Long-Term Debt-to-Capital Ratio | -0.01 | -0.01 | -0.16 | -0.64 | -0.34 |
| Financial Leverage Ratio | -0.22 | -0.28 | -0.44 | -1.17 | -0.37 |
| Debt Service Coverage Ratio | -0.88 | -0.84 | -1.98 | -2.65 | -0.40 |
| Interest Coverage Ratio | -3.84 | -5.53 | -12.44 | -5.73 | -2.05 |
| Debt to Market Cap | 0.05 | 0.23 | 0.23 | 0.20 | 0.32 |
| Interest Debt Per Share | 0.05 | 0.04 | 0.05 | 0.09 | 0.30 |
| Net Debt to EBITDA | -1.16 | -0.91 | -0.47 | 0.01 | -2.45 |
| Profitability Margins | |||||
| Gross Profit Margin | 74.45% | 28.57% | 36.73% | -523.08% | 24.69% |
| EBIT Margin | -336.25% | -29085.71% | -3276.53% | -28915.38% | -1135.80% |
| EBITDA Margin | -322.29% | -27728.57% | -3189.80% | -28361.54% | -1134.57% |
| Operating Profit Margin | -309.26% | -30114.29% | -3527.55% | -25638.46% | -2916.05% |
| Pretax Profit Margin | -416.69% | -34528.57% | -3560.20% | -33392.31% | -2555.56% |
| Net Profit Margin | -416.69% | -34528.57% | -3560.20% | -33392.31% | -2555.56% |
| Continuous Operations Profit Margin | -416.69% | -34528.57% | -3560.20% | -33392.31% | -2555.56% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 134.74% | 114.66% | 100.93% | 130.24% | 87.64% |
| Return on Assets (ROA) | -241.39% | -175.40% | -209.05% | -128.97% | -101.47% |
| Return on Equity (ROE) | 53.21% | 49.44% | 91.67% | 150.57% | 38.02% |
| Return on Capital Employed (ROCE) | 44.65% | 44.13% | 110.10% | 221.76% | 64.64% |
| Return on Invested Capital (ROIC) | 77.34% | 77.22% | 197.77% | 541.95% | 96.53% |
| Return on Tangible Assets | -241.39% | -175.40% | -209.05% | -128.97% | -101.47% |
| Earnings Yield | -7.55% | -28.10% | -44.45% | -44.52% | -26.68% |
| Efficiency Ratios | |||||
| Receivables Turnover | 191.75 | 2.33 | 14.00 | 2.17 | 1.76 |
| Payables Turnover | 0.08 | 0.00 | 0.03 | 0.04 | 0.02 |
| Inventory Turnover | 0.44 | 0.01 | 0.10 | 0.15 | 0.11 |
| Fixed Asset Turnover | 1.09 | 0.04 | 0.38 | 0.04 | 0.21 |
| Asset Turnover | 0.58 | 0.01 | 0.06 | 0.00 | 0.04 |
| Working Capital Turnover Ratio | -0.14 | -0.00 | -0.04 | -0.00 | -0.01 |
| Cash Conversion Cycle | -3720.72 | -109124.57 | -8162.88 | -7388.39 | -11029.93 |
| Days of Sales Outstanding | 1.90 | 156.43 | 26.07 | 168.46 | 207.28 |
| Days of Inventory Outstanding | 834.29 | 46209.00 | 3720.65 | 2469.38 | 3416.64 |
| Days of Payables Outstanding | 4556.91 | 155490.00 | 11909.60 | 10026.23 | 14653.85 |
| Operating Cycle | 836.19 | 46365.43 | 3746.72 | 2637.84 | 3623.92 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.02 | -0.03 | -0.05 | -0.12 |
| Free Cash Flow Per Share | -0.01 | -0.02 | -0.03 | -0.05 | -0.12 |
| Dividend Paid and CapEx Coverage Ratio | -7.03 | -6.43 | 0.00 | -47.68 | -113.71 |
| Capital Expenditure Coverage Ratio | -534.00 | 0.00 | 0.00 | -47.68 | -113.71 |
| Operating Cash Flow Coverage Ratio | -0.36 | -0.52 | -0.85 | -0.65 | -0.55 |
| Operating Cash Flow to Sales Ratio | -1.39 | -159.86 | -17.82 | -113.69 | -19.65 |
| Free Cash Flow Yield | -2.53% | -13.01% | -22.25% | -15.47% | -20.70% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -12.65 | -3.32 | -2.25 | -2.25 | -3.75 |
| Price-to-Sales (P/S) Ratio | 55.21 | 1228.69 | 80.09 | 750.12 | 95.79 |
| Price-to-Book (P/B) Ratio | -7.05 | -1.76 | -2.06 | -3.38 | -1.42 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -39.57 | -7.69 | -4.50 | -6.46 | -4.83 |
| Price-to-Operating Cash Flow Ratio | -39.65 | -7.69 | -4.50 | -6.60 | -4.87 |
| Price-to-Earnings Growth (PEG) Ratio | 2.29 | 0.09 | 0.04 | 0.13 | -0.01 |
| Enterprise Value Multiple | -18.29 | -5.34 | -2.98 | -2.63 | -10.90 |
| Enterprise Value | 45.22M | 10.37M | 9.32M | 9.70M | 10.01M |
| EV to EBITDA | -18.29 | -5.34 | -2.98 | -2.63 | -10.90 |
| EV to Sales | 58.96 | 1481.69 | 95.06 | 746.27 | 123.64 |
| EV to Free Cash Flow | -42.26 | -9.27 | -5.34 | -6.43 | -6.24 |
| EV to Operating Cash Flow | -42.34 | -9.27 | -5.34 | -6.56 | -6.29 |
| Tangible Book Value Per Share | -0.08 | -0.09 | -0.07 | -0.09 | -0.41 |
| Shareholders’ Equity Per Share | -0.08 | -0.09 | -0.07 | -0.09 | -0.41 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 |
| Net Income Per Share | -0.04 | -0.04 | -0.07 | -0.13 | -0.15 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.24 | 1.19 | 1.09 | 1.15 | 2.25 |
| Research & Development to Revenue | 0.61 | 75.14 | 2.33 | 5.92 | 0.85 |
| SG&A to Revenue | 3.23 | 226.29 | 30.58 | 231.31 | 26.81 |
| Stock-Based Compensation to Revenue | 0.49 | 17.14 | 18.43 | 106.23 | 2.81 |
| Income Quality | 0.33 | 0.46 | 0.50 | 0.34 | 0.77 |
Currency in USD

